메뉴 건너뛰기




Volumn 41, Issue 2, 2015, Pages 159-160

Marked response to 177lu prostate-specific membrane antigen treatment in patient with metastatic prostate cancer

Author keywords

177Lu PSMA treatment; 68Ga PSMA PET CT; Prostatic cancer

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN GA 68; PROSTATE SPECIFIC MEMBRANE ANTIGEN LU 177; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; EDETIC ACID; GLU-NH-CO-NH-LYS-(AHX)-((68)GA(HBED-CC)); LUTETIUM; OLIGOPEPTIDE;

EID: 84945257151     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0000000000001058     Document Type: Article
Times cited : (8)

References (8)
  • 1
    • 0032188742 scopus 로고    scopus 로고
    • Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases
    • Sweat SD, Pacelli A, Murphy GP, et al. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. 1998;52:637-640.
    • (1998) Urology. , vol.52 , pp. 637-640
    • Sweat, S.D.1    Pacelli, A.2    Murphy, G.P.3
  • 2
    • 68949116384 scopus 로고    scopus 로고
    • Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis
    • Mannweiler S, Amersdorfer P, Trajanoski S, et al. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol On col Res. 2009;15:167-172.
    • (2009) Pathol on Col Res. , vol.15 , pp. 167-172
    • Mannweiler, S.1    Amersdorfer, P.2    Trajanoski, S.3
  • 3
    • 84899755833 scopus 로고    scopus 로고
    • Synthesis, radiolabelling and in vitro characterization of the gallium-68-, yttrium-90-and lutetium-177-labelled PSMA ligand, CHX-A-DTPA-DUPA-Pep
    • Baur B, Solbach C, Andreolli E, et al. Synthesis, radiolabelling and in vitro characterization of the gallium-68-, yttrium-90-and lutetium-177-labelled PSMA ligand, CHX-A-DTPA-DUPA-Pep. Pharmaceuticals (Basel). 2014;7: 517-529.
    • (2014) Pharmaceuticals (Basel). , vol.7 , pp. 517-529
    • Baur, B.1    Solbach, C.2    Andreolli, E.3
  • 4
    • 84859991899 scopus 로고    scopus 로고
    • 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging
    • 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23:688-697.
    • (2012) Bioconjug Chem. , vol.23 , pp. 688-697
    • Eder, M.1    Schäfer, M.2    Bauder-Wüst, U.3
  • 5
    • 84942909663 scopus 로고    scopus 로고
    • PSMA PET/CTwith Glu-urea-Lys-(Ahx)-[68Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer [published online ahead of print July 11, 2015]
    • Giesel FL, Fiedler H, Stefanova M, et al. PSMA PET/CTwith Glu-urea-Lys-(Ahx)-[68Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer [published online ahead of print July 11, 2015]. Eur J Nucl Med Mol Imaging. 2015.
    • (2015) Eur J Nucl Med Mol Imaging.
    • Giesel, F.L.1    Fiedler, H.2    Stefanova, M.3
  • 6
    • 84940890584 scopus 로고    scopus 로고
    • A high-affinity [(18)F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer
    • Ganguly T, Dannoon S, Hopkins MR, et al. A high-affinity [(18)F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer. Nucl Med Biol. 2015;42:780-787.
    • (2015) Nucl Med Biol. , vol.42 , pp. 780-787
    • Ganguly, T.1    Dannoon, S.2    Hopkins, M.R.3
  • 7
    • 79952017967 scopus 로고    scopus 로고
    • 177Lu-labelled anti-PSMA antibody as a new radioimmunotherapeutic agent against prostate cancer
    • 177Lu-labelled anti-PSMA antibody as a new radioimmunotherapeutic agent against prostate cancer. In Vivo. 2011;25:55-59.
    • (2011) Vivo. , vol.25 , pp. 55-59
    • Behe, M.1    Alt, K.2    Deininger, F.3
  • 8
    • 84943699054 scopus 로고    scopus 로고
    • 177Lu]lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer
    • 177Lu]lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:987-988.
    • (2015) Eur J Nucl Med Mol Imaging. , vol.42 , pp. 987-988
    • Kratochwil, C.1    Giesel, F.L.2    Eder, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.